How a False Alarm Affects Future Cancer Screenings
MONDAY, April 23, 2018 -- A cancer scare could increase the chances that you'll be diligent about recommended screenings in the future, a new study finds. People who got a false-positive result on a breast or prostate cancer screening test were more...
CONCLUSIONS: Afro-Caribbean populations in French West Indies share the same major clinical and pathological risk factors of BCR after RP identified in other ethnic groups. Perioperative blood loss appears to be an additional and independent predictive factor of BCR. LEVEL OF PROOF: 4. PMID: 29789237 [PubMed - as supplied by publisher]
CONCLUSION: A reduction of LUTS is observed in patients with locally advanced or metastatic prostate cancer treated with triptorelin in routine practice. This is in agreement with similar observational studies of triptorelin conducted in other countries. LEVEL OF PROOF: 4. PMID: 29789236 [PubMed - as supplied by publisher]
CONCLUSION: Mp-MRI is a useful exam for selecting patients eligible for AS even if the situation remains unclear after prostate biopsies including targeted biopsies. Upon confirmation by further studies, mp-MRI should be considered as an independent criterion before entering an AS program. LEVEL OF EVIDENCE: 4. PMID: 29789235 [PubMed - as supplied by publisher]
CONCLUSIONS: In this study obese men do not appear to have a significant increase in risk of PSMs at RP compared to lean and overweight men when operated by a minimally invasive approach. The magnified vision and increased access to the pelvis allowed by a laparoscopic and robotic-assisted approach may be accountable for our findings. Larger studies are needed to validate our results. LEVEL OF PROOF: 4. PMID: 29789234 [PubMed - as supplied by publisher]
Is active surveillance for low-risk prostate cancer preferred in men who strongly want to preserve sexual function?Journal of the National Cancer Institute
Publication date: Available online 24 May 2018 Source:European Urology Author(s): Giovanni Lughezzani, Nicolo’ Maria Buffi, Massimo Lazzeri
Publication date: Available online 24 May 2018 Source:European Urology Author(s): Vincenza Conteduca, Giorgia Gurioli, Ugo De Giorgi
Erleada (apalutamide) is the first treatment approved for nonmetastatic, castration-resistant prostate cancer.If patients prescribed apalutamide are also taking other drugs metabolized by the same cytochrome P-450 isoenzyme systems, the circulating levels of apalutamide may be altered.
Saw palmetto is an herbal remedy with many potential uses in healthcare. One such use is the treatment of benign prostate hyperplasia (BPH). Although a popular remedy, research into the herb ’s efficacy is still ongoing and the results to date are inconclusive. Here, we look at the other treatments also available.
Findings for men with intermediate - and high - risk prostate cancer